Tandem secures CE mark for AID systems in T2D and T1D with pregnancy

Tandem Diabetes Care has received a CE mark for expanded indications of its automated insulin delivery (AID) systems in ...
The American Journal of Managed Care

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...
Healio

Long-term glycemic outcomes similar for children using Control-IQ, Omnipod 5 systems

Children with type 1 diabetes had similar long-term glycemic outcomes with two different automated insulin delivery systems, ...
Hosted on MSN

FDA clears Control-IQ+ insulin tech for pregnancy use

The FDA has approved Tandem Diabetes Care’s Control-IQ+ automated insulin delivery technology for use during pregnancy in people with type 1 diabetes. The decision follows a clinical trial showing the ...
Nasdaq

Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...